健世科技(09877.HK)LuX-Valve Plus关键性注册临床试验获美FDA批准

阿斯达克财经

02/08

健世科技－Ｂ(09877.HK) 公布，公司自主研发的经血管三尖瓣介入置换系统LuX-Valve Plus，正式获美国食品及药品监督管理局“FDA”对其关键性注册临床试验的无附加条件的试验用器械豁免批准，标志该产品在美国的注册临床进程及集团全球化战略取得重要突破性进展。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2026-02-06 16:25。)AASTOCKS新闻

网页链接

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2609711576"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2609711576\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2609711576?lang=zh_CN&edition=fundamental","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20221108130510223_s.jpg","is_english":false,"pubTime":"2026-02-08 19:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2609711576","market":"hk","top_or_hot":-1,"title":"健世科技(09877.HK)LuX-Valve Plus关键性注册临床试验获美FDA批准","media":"阿斯达克财经","content":"<div>\n<p>健世科技－Ｂ(09877.HK) 公布，公司自主研发的经血管三尖瓣介入置换系统LuX-Valve Plus，正式获美国食品及药品监督管理局“FDA”对其关键性注册临床试验的无附加条件的试验用器械豁免批准， 标志该产品在美国的注册临床进程及集团全球化战略取得重要突破性进展。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2026-02-06 16:25。)AASTOCKS新闻</p>\n\n<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1501840/latest-news/AAFN\">网页链接</a>\n\n</div>\n","source":"aastocks_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>健世科技(09877.HK)LuX-Valve Plus关键性注册临床试验获美FDA批准</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n健世科技(09877.HK)LuX-Valve Plus关键性注册临床试验获美FDA批准\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-08 19:28 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1501840/latest-news/AAFN><strong>阿斯达克财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>健世科技－Ｂ(09877.HK) 公布，公司自主研发的经血管三尖瓣介入置换系统LuX-Valve Plus，正式获美国食品及药品监督管理局“FDA”对其关键性注册临床试验的无附加条件的试验用器械豁免批准， 标志该产品在美国的注册临床进程及集团全球化战略取得重要突破性进展。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2026-02-06 16:25。)AASTOCKS新闻</p>\n\n<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1501840/latest-news/AAFN\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1100","symbol_name":"医疗保健设备","start_time":0,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1501840/latest-news/AAFN","article_id":"2609711576","we_media_id":null,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20221108130510223_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1501840/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2609711576","pubTimestamp":1770550080,"columns":[],"sourceInfo":{"source_id":"aastocks_highlight","name":"阿思達克財經"},"weMediaInfo":null,"summary":"健世科技－Ｂ(09877.HK) 公布，公司自主研发的经血管三尖瓣介入置换系统LuX-Valve Plus，正式获美国食品及药品监督管理局“FDA”对其关键性注册临床试验的无附加条件的试验用器械豁免批准， 标志该产品在美国的注册临床进程及集团全球化战略取得重要突破性进展。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2026-02-06 16:25。)AASTOCKS新闻","collect":0,"end_time":0,"defaultTopTitle":"aastocks.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1100":"医疗保健设备","09877":"健世科技-B"},"translate_title":"Jianshi Technology (09877. HK) LuX-Valve Plus pivotal registration clinical trial was approved by the US FDA","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09877":1.5},"content_text":"健世科技－Ｂ(09877.HK) 公布，公司自主研发的经血管三尖瓣介入置换系统LuX-Valve Plus，正式获美国食品及药品监督管理局“FDA”对其关键性注册临床试验的无附加条件的试验用器械豁免批准， 标志该产品在美国的注册临床进程及集团全球化战略取得重要突破性进展。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2026-02-06 16:25。)AASTOCKS新闻","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}